| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.1 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.059 | 0.1 |
| mRNA | JW-7-52-1 | GDSC1000 | pan-cancer | AAC | -0.079 | 0.1 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.071 | 0.1 |
| mRNA | AZD-2281 | CTRPv2 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | hyperforin | CTRPv2 | pan-cancer | AAC | 0.059 | 0.1 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.052 | 0.1 |